Literature DB >> 28778997

Involvement of Nuclear Factor κB, not Pregnane X Receptor, in Inflammation-Mediated Regulation of Hepatic Transporters.

Walaa A Abualsunun1, Micheline Piquette-Miller2.   

Abstract

Endotoxin-induced inflammation decreases the hepatic expression of several drug transporters, metabolizing enzymes, and nuclear transcription factors, including pregnane X receptor (PXR). As the nuclear factor κB (NF-κB) is a major mediator of inflammation, and reciprocal repression between NF-κB and PXR signaling has been reported, the objective of this study was to examine whether NF-κB directly regulates the expression of transporters or exerts its effect indirectly via PXR. PXR-deficient (-/-) or wild-type (+/+) male mice were dosed with the selective NF-κB inhibitor PHA408 (40 mg/kg i.p.) or vehicle (n = 5-8/group), followed by endotoxin (5 mg/kg) or saline 30 minutes later. Animals were sacrificed at 6 hours; samples were analyzed using quantitative reverse-transcription polymerase chain reaction and Western blots. Endotoxin induced tumor necrosis factor-α, interleukin (IL)-6, IL-1β, and inducible nitric oxide synthase in PXR (+/+) and (-/-) mice. As compared with saline controls, endotoxin administration imposed 30%-70% significant decreases in the expression of Abcb1a, Abcb11, Abcc2, Abcc3, Abcg2, Slc10a1, Slco2b1, and Slco1a4 in PXR (+/+) and (-/-) mice to a similar extent. Preadministration of PHA408 attenuated endotoxin-mediated changes in both PXR (+/+) and (-/-) mice (P < 0.05). Our findings demonstrate that endotoxin activates NF-κB and imposes a downregulation of numerous ATP-binding cassette and solute carrier transporters through NF-κB in liver and is independent of PXR. Moreover, inhibition of NF-κB attenuates the impact of endotoxin on transporter expression. As NF-κB activation is involved in many acute and chronic disease states, disease-induced changes in transporter function may be an important source of variability in drug response. This information may be useful in predicting potential drug-disease interactions.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28778997     DOI: 10.1124/dmd.117.076927

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Role of Elevated SFLT-1 on the Regulation of Placental Transporters in Women With Pre-Eclampsia.

Authors:  Dea Kojovic; Natalie V Workewych; Micheline Piquette-Miller
Journal:  Clin Transl Sci       Date:  2020-02-03       Impact factor: 4.689

2.  Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats.

Authors:  Navaz Karimian Pour; Eliza R McColl; Micheline Piquette-Miller
Journal:  Pharmaceutics       Date:  2019-11-22       Impact factor: 6.321

Review 3.  Regulation of Drug Transport Proteins-From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.

Authors:  Kim L R Brouwer; Raymond Evers; Elizabeth Hayden; Shuiying Hu; Cindy Yanfei Li; Henriette E Meyer Zu Schwabedissen; Sibylle Neuhoff; Stefan Oswald; Micheline Piquette-Miller; Chitra Saran; Noora Sjöstedt; Jason A Sprowl; Simone H Stahl; Wei Yue
Journal:  Clin Pharmacol Ther       Date:  2022-05-24       Impact factor: 6.903

Review 4.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

Review 5.  Regulation of CAR and PXR Expression in Health and Disease.

Authors:  Martine Daujat-Chavanieu; Sabine Gerbal-Chaloin
Journal:  Cells       Date:  2020-10-31       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.